Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Cardiotoxicity × empagliflozin × Clear all

Phase

Status

Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Cardiotoxicity 1 Breast Neoplasms 1

Interventions

Echocardiography 4 Exercise 2 Electrocardiography 2 sulforaphane 1 schizandrin 1 sacubitril and valsartan sodium hydrate drug combination 1 pegfilgrastim 1 nicotinamide-beta-riboside 1 fructus schizandrae, radix ginseng, radix ophiopogonis drug combination 1 empagliflozin 1 dapagliflozin 1 Watchful Waiting 1 Vincristine 1 Tablets 1 Rituximab 1 Proton Therapy 1 Proteins 1 Prednisolone 1 Observation 1 Medical History Taking 1 Lenalidomide 1 Laser-Doppler Flowmetry 1 Environmental Biomarkers 1 Echocardiography, Stress 1 Doxorubicin 1 Dexrazoxane 1 Cyclophosphamide 1 Clinical Laboratory Techniques 1 Carvedilol 1 Blood Pressure Determination 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05271162 2025-11-21

EMPACT

Maria Sklodowska-Curie National Research Institute of Oncology

Phase 3 Recruiting

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡